Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA approves BioSphere's embolic catheter:

This article was originally published in Clinica

Executive Summary

BioSphere Medical has gained US FDA approval to sell its EmboCath hydrophilic infusion catheter, which can be used in conjunction with the firm's microsphere technology. The EmboCath catheter will offer physicians a more targeted and controlled method for delivery of embolic material compared with standard angiographic catheters, said the Rockland, Massachusetts firm. The company also claims that EmboCath is a cost-effective alternative to currently available high-end micro-catheters, used commonly in embolotherapy procedures. BioSphere also plans to bring the product into Europe, pending CE-mark approval.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts